Inderjeet S Bharaj

Dr. Inderjeet S Bharaj

Department of Cardiology, UCSF Fresno, Fresno, California, USA
orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 September 2025 in Biomedicines
Verified
Journal Article
Open access
PDF file
Inderjeet S BharajInderjeet S Bharaj
Inderjeet S Bharaj
Ajit BrarAjit Brar
Ajit Brar
AKAayushi Nilesh Kacheria
Aayushi Nilesh Kacheria
KPKaren Purewal
Karen Purewal
ASAustin Simister
Austin Simister
KVKrishnaswami Vijayaraghavan
Krishnaswami Vijayaraghavan
Cardiovascular-kidney-metabolic (CKM) syndrome is a multifaceted, systemic disorder characterized by the interplay of cardiovascular disease (CVD), chronic kidney disease (CKD), type 2 diabetes mellitus (T2DM), and obesity. This review synthesizes current and emerging therapeutic strategies aimed at addressing the shared pathophysiologic mechanisms driving CKM progression, such as insulin resistance, inflammation, oxidative stress, and neurohormonal activation. Established pharmacotherapies that include sodium-glucose cotransporter 2 (SGLT2) inhibitors, glucagon-like peptide-1 receptor agonists (GLP-1 RAs), and nonsteroidal mineralocorticoid receptor antagonists like finerenone have demonstrated robust efficacy in reducing cardiovascular events, slowing renal decline, and improving metabolic outcomes. Additionally, novel agents targeting lipoprotein(a), interleukin-6, and hepatic fat accumulation are expanding the therapeutic landscape. RNA-based therapies, including antisense oligonucleotides (ASOs) and small interfering RNAs (siRNAs), are designed to modulate lipoprotein(a) and PCSK9 expression. Artificial intelligence (AI) is also emerging as a transformative tool for personalized CKM management, enhancing risk prediction and clinical decision-making. The review highlights the relevance of metabolic dysfunction-associated steatotic liver disease (MASLD) as a CKM modifier and discusses the approval of resmetirom, a selective thyroid hormone receptor β agonist, for noncirrhotic MASH. By integrating evidence from clinical trials, mechanistic studies, and emerging technologies, this review provides a comprehensive resource for clinicians and researchers navigating the evolving field of CKM syndrome.

17 September 2025 in Radiology Case Reports
Verified
Journal Article
Open access
Inderjeet S BharajInderjeet S Bharaj
Inderjeet S Bharaj
ETEi Ei Thwe
Ei Ei Thwe
IPInderbir Padda
Inderbir Padda
RMRavi Mann
Ravi Mann
BUBaljeet Uppal
Baljeet Uppal
MKMerick Kirshner
Merick Kirshner
Aortic calcification is associated with an increased risk of major adverse cardiovascular events, and while cases have been reported for its management, no expert consensus or guidelines currently exist. An 81-year-old male presented with recurrent falls and was diagnosed with severe symptomatic aortic stenosis (AS) and coronary artery disease (CAD) requiring high-risk percutaneous coronary intervention (PCI) and transcatheter aortic valve replacement (TAVR). Severe aortoiliac calcifications complicated clinical decision-making, posing a challenge to large-bore sheath placement. After heart-team review, shockwave intravascular lithotripsy (IVL) with bilateral 7×60 mm balloons was utilized to deliver sonic pressure waves at low inflation pressures to selectively fracture intimal and medial calcium. Improved vessel compliance facilitated Impella-assisted PCI and staged TAVR. This case demonstrates that IVL may be a viable option for aortic calcification when alternative approaches are limited. Its familiar balloon-based design and low-pressure inflation enhance its appeal. While procedural vascular risks do exist, they remain low and can be minimized with proper device sizing and technique.

8 September 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
Inderjeet S BharajInderjeet S Bharaj
Inderjeet S Bharaj
Ajit BrarAjit Brar
Ajit Brar
AKAayushi Nilesh Kacheria
Aayushi Nilesh Kacheria
KPKaren Purewal
Karen Purewal
ASAustin Simister
Austin Simister
KVKrishnaswami Vijayaraghavan
Krishnaswami Vijayaraghavan
Cardiovascular-kidney-metabolic (CKM) syndrome is a multifaceted, systemic disorder characterized by the interplay of cardiovascular disease (CVD), chronic kidney disease (CKD), type 2 diabetes mellitus (T2DM), and obesity. This review synthesizes current and emerging therapeutic strategies aimed at addressing the shared pathophysiologic mechanisms driving CKM progression, such as insulin resistance, inflammation, oxidative stress, and neurohormonal activation. Established pharmacotherapies that include sodium-glucose cotransporter 2 (SGLT2) inhibitors, glucagon-like peptide-1 receptor agonists (GLP-1 RAs), and nonsteroidal mineralocorticoid receptor antagonists like finerenone have demonstrated robust efficacy in reducing cardiovascular events, slowing renal decline, and improving metabolic outcomes. Additionally, novel agents targeting lipoprotein(a), interleukin-6, and hepatic fat accumulation are expanding the therapeutic landscape. RNA-based therapies, including antisense oligonucleotides (ASOs) and small interfering RNAs (siRNAs), are designed to modulate lipoprotein(a) and PCSK9 expression. Artificial intelligence (AI) is also emerging as a transformative tool for personalized CKM management, enhancing risk prediction and clinical decision-making. The review highlights the relevance of metabolic dysfunction-associated steatotic liver disease (MASLD) as a CKM modifier and discusses the approval of resmetirom, a selective thyroid hormone receptor β agonist, for noncirrhotic MASH. By integrating evidence from clinical trials, mechanistic studies, and emerging technologies, this review provides a comprehensive resource for clinicians and researchers navigating the evolving field of CKM syndrome.

15 December 2025 in JACC: Case Reports
Verified
Journal Article
Open access
Inderjeet S BharajInderjeet S Bharaj
Inderjeet S Bharaj
ETEi Ei Thwe
Ei Ei Thwe
IPInderbir Padda
Inderbir Padda
HPHao Pan
Hao Pan
ALAkil Loli
Akil Loli
BABasil Alkhatib
Basil Alkhatib
Migration of gonadal vein embolization coils into the heart is rare but can lead to serious complications such as thrombosis, infection, or perforation. A 27-year-old woman presented with chest pain 2 years after bilateral gonadal vein embolization. Imaging revealed a migrated coil adherent to the right atrium. Initial femoral snaring attempts caused coil fragmentation. Successful retrieval was achieved using a combined balloon-assisted trapping technique and AngioVac aspiration via femoral and internal jugular access. The patient recovered uneventfully without residual fragments or complications. Endothelialization of migrated coils can impede percutaneous retrieval and increase procedural complexity. Multimodal strategies integrating aspiration and mechanical trapping may enhance success and avoid surgery. Migrated embolization coils can be safely retrieved percutaneously using advanced multimodal techniques. Preprocedural imaging, multidisciplinary planning, and access to specialized equipment are essential for successful and complication-free outcomes.

17 March 2026 in Metabolites
Verified
Journal Article
Open access
PDF file
GSGurkaranvir Singh
Gurkaranvir Singh
Inderjeet S BharajInderjeet S Bharaj
Inderjeet S Bharaj
JBJoey Bettencourt
Joey Bettencourt
ASAmarjit Kaur Sekhon
Amarjit Kaur Sekhon
GSGurparvesh Singh
Gurparvesh Singh
AAAmbar Andrade
Ambar Andrade
Background: Tyrosine kinase inhibitors (TKIs) have transformed cancer therapy; however, they are associated with cardiovascular toxicity. Metabolomics provides a comprehensive framework for identifying early biochemical disruptions that precede clinical manifestations and for formulating mechanism-based intervention strategies. Methods: We conducted a narrative synthesis of published preclinical and translational studies on TKI cardiotoxicity, focusing on untargeted and targeted metabolomic findings and complementary proteomic and transcriptomic data. Functional validation was performed using rodent and cellular models. Mechanistic themes were identified, and implications for biomarker panels, multi-omic integration, and metabolomics-guided interventions were proposed. Conclusions: Metabolomic analyses of various TKIs identified convergent signatures along three interconnected axes: (1) mitochondrial bioenergetic dysfunction characterized by impaired long-chain fatty acid oxidation and adenylate depletion; (2) disruption of endothelial nitric oxide signaling with redox imbalance, including increased nitrotyrosine, Nox activation, and eNOS uncoupling; and (3) an inflammatory metabolic profile marked by elevated branched-chain and aromatic amino acids, creatine, and osmolytes. Rodent models of sunitinib and sorafenib replicate these signatures and demonstrate histological injury, contractile dysfunction, and fibrosis. Preclinical intervention data, particularly restoration of myocardial carnitine, AMPK signaling, and fatty acid oxidation by L-carnitine, provide proof of concept for metabolomics-guided cardioprotection. Metabolomics can identify mechanistic biomarkers that facilitate the early detection, risk stratification, and targeted prevention of TKI-induced cardiovascular injury. Translation into precision cardio-oncology requires prospective validation, standardized assays, and biomarker-driven interventional trials.

8 October 2025 in American Journal of Case Reports
Verified
Journal Article
Open access
Inderjeet S BharajInderjeet S Bharaj
Inderjeet S Bharaj
Ajit BrarAjit Brar
Ajit Brar
BMBillal Mohmand
Billal Mohmand
MMMichael Morris
Michael Morris
BYBeeletsega T. Yeneneh
Beeletsega T. Yeneneh
BACKGROUND Acute myopericarditis can clinically and electrocardiographically mimic ST-elevation myocardial infarction (STEMI), leading to misdiagnosis and delayed treatment. In people living with HIV (PLWH), particularly those untreated, impaired immunity and viral-driven inflammation amplify cardiac involvement. Autopsy data suggest a myocarditis prevalence rate of up to 50% in AIDS patients, yet clinically overt cases remain rare. Diagnostic ambiguity can precipitate unnecessary invasive procedures and contribute to HIV-associated cardiomyopathy, an AIDS-defining illness. CASE REPORT A 62-year-old white man with untreated HIV, noncompliance with antiretroviral therapy, heart failure with reduced ejection fraction (HFrEF), and active substance use presented with 3 days of chest pressure and progressive dyspnea. Pre-hospital ECG demonstrated inferolateral ST-segment elevations, triggering STEMI activation. Coronary angiography revealed multivessel obstructive stenoses with preserved TIMI-3 flow and no thrombotic occlusion. Transthoracic echocardiography showed global left ventricular hypokinesis (EF 24%) and moderate pericardial effusion. Cardiac magnetic resonance imaging demonstrated elevated native T1 times, diffuse pericardial enhancement, and absent late gadolinium uptake, confirming acute myopericarditis. Serologic evaluation included coccidioidomycosis titers, viral panel, and tuberculosis workup. Treatment comprised colchicine, ibuprofen, aspirin, high-intensity statin, goal-directed medical therapy for heart failure, reinitiation of antiretroviral therapy, and prophylaxis for opportunistic infections. CONCLUSIONS This case illustrates the diagnostic challenge of distinguishing myopericarditis from STEMI in people living with HIV. Accurate recognition using advanced imaging techniques such as cardiac MRI can prevent unnecessary invasive procedures and facilitate targeted therapy. Multidisciplinary care is vital to optimizing outcomes, particularly in patients with complex comorbidities and barriers to care.